Indication

Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.

Medicine details

Medicine name:
axicabtagene ciloleucel (Yescarta)
SMC ID:
SMC2628
Pharmaceutical company
Gilead Sciences Ltd
BNF chapter
Nutrition and blood
Submission type
Full
Publication due date:
11 March 2024
SMC meeting date:
06 February 2024
Patient group submission deadline:
TBC